If available, request a "kid's size" bowl which provides a more appropriate portion
The research is relevant to drug-target discovery but does not establish a human strength, exercise-performance or healthy-ageing effect
Clinical Evidence In a 2021 clinical trial (SURPASS-2), tirzepatide was found to have greater reductions in hemoglobin A1c (HbA1c) and body weight than semaglutide 1 mg in people with type 2 diabetes [6]
Recent head-to-head studies suggest that Mounjaro may offer even greater average weight loss compared to Ozempic at higher doses
In the SURMOUNT-1 trial, participants without diabetes lost an average of 15-22% of their body weight over 72 weeks, depending on the dose (5-15mg)
Mechanism of Action Compared AOD-9604 and Tesamorelin both influence fat metabolism, but through opposite ends of the growth hormone system: AOD-9604 acts directly on fat cells without engaging the GH/IGF-1 axis at all, while Tesamorelin works by turning that axis on